News | Radiopharmaceuticals and Tracers | December 28, 2017

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

PET tracer helps identify ability of key enzyme to inhibit amyloid-β protein generation in mouse models

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

December 28, 2017 — In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the first large-scale longitudinal imaging study to evaluate BACE1 inhibition with micro-PET (positron emission tomography) in mouse models of Alzheimer’s disease. PET imaging has been established as an excellent identifier of the amyloid plaque and tau tangles that characterize Alzheimer’s disease. Now it is proving to be an effective way to gauge treatment effectiveness.

The tracer makes it possible to image the effects of chronic administration of an inhibitor for an enzyme, called beta (β)-site amyloid precursor protein-cleaving enzyme 1 (BACE1), which cuts off protein fragments that can lead to amyloid-β development and is more prevalent in brains affected by Alzheimer’s. It does this by binding to BACE1.

The study compared control mice with those genetically-altered to have Alzheimer’s, and tested 18F-florbetapir (18F-AV45) along with two other tracers, 18F-FDG PET and 18F-PBR111. The mice received the BACE inhibitor at 7 weeks, then brain metabolism, neuroinflammation and amyloid-β pathology were measured using a micro-PET (μPET) scanner and each of the tracers. Baseline scans were done at 6-7 weeks and follow-up scans at 4,7 and 12 months. 18F-AV45 uptake was measured at 8 and 13 months of age. After the final scans, microscopic studies were performed.

While all three tracers detected pathological differences between the genetically modified mice and the controls, only 18F-AV45 showed the effects of inhibitor treatment by identifying reduced amyloid-β pathology in the genetically modified mice. This was confirmed in the microscopic studies.

The team of the Molecular Imaging Center Antwerp, Belgium, however warned, “This study clearly showed that accurate quantification of amyloid-beta tracers is critically important and that the non-specific uptake in the brain of subjects might be underestimated for some existing Alzheimer’s tracers that have fast metabolization profiles. The aim of this translational research is advancing results discovered at the bench so that they can be applied to patients at the bedside.”

For more information: www.jnm.snmjournals.org

Related Content

Master Supply Agreement encompasses clinical development and commercial supply for Clarity’s Cu-67-based candidates to treat neuroblastoma, breast and prostate cancers, among others
News | Radiopharmaceuticals and Tracers | June 22, 2021
June 22, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercia
A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.

Figure 1. Case example: A 54-year-old man with a history of RP+LND and a subsequent PSA of 1.25 ng/mL had no evidence of disease by baseline imaging. Piflufolastat F 18 (18F-DCFPyL)- PET/CT accurately detected biochemically recurrent prostate cancer with the PSMA PET/CT scan identifying positive left (left panel) and right peri-rectal lymph nodes (right panel).

News | Prostate Cancer | June 21, 2021
June 21, 2021 — A phase III clinica...
A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed.

Figure 1. Tau accumulation over one year measured in composite A) mesial temporal ROI; and B) temporoparietal ROI in cognitively unimpaired participants (blue) and cognitively impaired participants (red). The CI group included participants with clinical mild cognitive impairment and dementia. Higher rates of tau accumulation were observed in participants on the AD continuum (CU Aβ+ve and CI Aβ+ve). Participants with the highest baseline tau and rates of tau accumulation were younger and more likely to be CI Aβ+ve. Image courtesy of SNMMI

News | PET Imaging | June 16, 2021
June 16, 2021 — A novel positron emission tomography (PET
SNMMI's Image of the Year is a detailed depiction of areas of cognitive impairment, neurological symptoms and comparison of impairment over a six-month time frame

Figure 1. A: COVID-19-related spatial covariance pattern of cerebral glucose metabolism overlaid onto an MRI template. Voxels with negative region weights are color-coded in cool colors, and regions with positive region weights in hot colors. B: Association between the expression of COVID-19-related covariance pattern and the Montreal Cognitive Assessment (MoCA) score adjusted for years of education. Each dot represents individual patient. C: Results of a statistical parametric mapping analysis. Upper row illustrates regions that show significant increases of normalized FDG uptake in COVID-19 patients at 6-months follow-up compared to the subacute stage (paired t test, p < 0.01, false discovery rate-corrected). Bottom row depicts regions that still show significant decreases of normalized FDG uptake in COVID-19 patients at 6-months follow-up compared to the age-matched control cohort at an exploratory statistical threshold (two-sample t test, p < 0.005). Image Credit: G Blazhenets et al., Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg

News | PET Imaging | June 16, 2021
June 16, 2021 — The effects of COVID-19 on the b
The prevalence of genetic mutations associated with breast cancer in Black and white women is the same, according to a new JAMA Oncology study of nearly 30,000 patients led by researchers in the Basser Center for BRCA at the Abramson Cancer Center.

Getty Images

News | Women's Health | June 15, 2021
June 15, 2021 — The prevalence of genetic mutations associated with breast cancer in Black and white women is the sam
A new imaging technique has the potential to detect neurological disorders — such as Alzheimer's disease — at their earliest stages, enabling physicians to diagnose and treat patients more quickly. Termed super-resolution, the imaging methodology combines position emission tomography (PET) with an external motion tracking device to create highly detailed images of the brain.

Result of the Hoffman brain phantom study. Top row: same PET slice reconstructed with A) 2mm static OSEM, B) 1mm static OSEM, C) proposed SR method and D) corresponding CT slice (note that the CT image can be treated as a high-resolution reference). Middle row: zoom on region of interest for corresponding images. Bottom row: Line profiles for corresponding data. Image created by Y Chemli, et al., Gordon Center for Medical Imaging: Department of Radiology Massachusetts General Hospital, Harvard Medical School, Boston, MA.

News | PET Imaging | June 14, 2021
June 14, 2021 — A new imaging technique has the potential to detect neurological disorders — such as...
Positron emission tomography (PET) using a 68Ga-labeled fibroblast activation protein inhibitor (FAPI) can noninvasively identify and monitor pulmonary fibrosis, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.

A) Axial CT images through the mouse lungs at 7 and 14 days after intratracheal administration of bleomycin or saline (as a control), demonstrating increased lung fibrosis in the bleomycin group (white arrows). (B) CT attenuation histograms in Hounsfield units (HU) after lung segmentation demonstrate increased attenuation in the lungs in the bleomycin group than the control group (p <0.05), consistent with increasing fibrosis (n=3). (C) Representative axial PET/CT fusion images at 20 and 60 min demonstrating increased FAPI uptake in the lungs of the bleomycin group (white arrows) with no significant uptake in the control group (yellow arrows). (D) Time-activity curve of lung uptake ROI analysis demonstrating higher FAPI uptake in the lungs of the bleomycin group than the control (p < 0.05), 14 days after bleomycin (n=3). (E) Ex vivo biodistribution data of lung tissue demonstrating higher radiotracer uptake in the lungs of the bleomycin group than the control (n=3). *p<0.05, **p<0.01. Image created by CA Ferreira et al., University of Wisconsin-Madison, Madison, WI.

News | PET-CT | June 14, 2021
June 14, 2021 — Positron emission tomography (PET) using
Prediction performance of DL compared to quantitative measures and Kaplan-Meier curves for quartiles of DL. Image created by Singh et al., Cedars-Sinai Medical Center, Los Angeles, CA.

Prediction performance of DL compared to quantitative measures and Kaplan-Meier curves for quartiles of DL. Image created by Singh et al., Cedars-Sinai Medical Center, Los Angeles, CA.

News | SPECT Imaging | June 14, 2021
June 14, 2021 — An advanced artificial i...
The new X-ray scanner can provide detailed information about the internal makeup of rocks, which could be useful for archaeologists studying fossils or miners making decisions about which ore to use in their extraction facilities. Image courtesy of Joel Greenberg, Duke University

The new X-ray scanner can provide detailed information about the internal makeup of rocks, which could be useful for archaeologists studying fossils or miners making decisions about which ore to use in their extraction facilities. Image courtesy of Joel Greenberg, Duke University

News | X-Ray | June 10, 2021
June 10, 2021 — Engineers at Duke University have demonstrated a prot